Medtronic MDT Diabetes — Net Sales
Other segment segments
Similar metrics at other companies
Other financials
Where this comes from
Reported directly by Medtronic in its filing.
Tagged under the XBRL concept us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax.
The official record: Medtronic’s 10-K, filed June 18, 2026, on SEC EDGAR. View the filing →
Ask your AI about Medtronic's diabetes — net sales.
Connect your AI assistant and compare segments, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is Medtronic's diabetes — net sales?
- Medtronic (MDT) reported diabetes — net sales of $838M in Q1 2026.
- How has Medtronic's diabetes — net sales changed year-over-year?
- Medtronic's diabetes — net sales increased by 15.1% year-over-year, from $728M to $838M.
- What is the long-term trend for Medtronic's diabetes — net sales?
- Over 5 years (2021 to 2026), Medtronic's diabetes — net sales has grown at a 5.2% compound annual growth rate (CAGR), from $2.41B to $3.11B.
- What does diabetes — net sales mean?
- Total revenue earned from selling diabetes products after accounting for returns and discounts.
- How do you interpret diabetes — net sales?
- An increase indicates strong market demand and successful commercial execution, while a decrease signals competitive pressure or market saturation.
- How does diabetes — net sales compare across companies?
- Standard revenue metric for any business segment across all industries.